Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers
NCT: NCT07566091 · NOT_YET_RECRUITING
Brief Summary
The objective of this study is to demonstrate the primary hypothesis that, in patients with chronic and acute coronary syndromes requiring percutaneous coronary intervention (PCI), the novel sirolimus-ascorbic acid eluting stent (D+Storm Novonix) is non-inferior to the standard treatment, the everolimus-eluting stent (Synergy XD), with respect to the incidence of target lesion failure (TLF) at 1 year after treatment, where TLF is defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically driven target-lesion revascularization.
Frequently Asked Questions
What is Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers?
Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers is a clinical trial registered under NCT07566091. Current status: NOT_YET_RECRUITING.
What is the status of NCT07566091?
The current status of NCT07566091 (Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers) is: NOT_YET_RECRUITING.
When did Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers start?
Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers started on 2026-06-15.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.